Pfizer Inc.

BOVESPA:PFIZ34 Stock Report

Market Cap: R$909.0b

Pfizer Past Earnings Performance

Past criteria checks 0/6

Pfizer's earnings have been declining at an average annual rate of -1.7%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 10.5% per year. Pfizer's return on equity is 4.7%, and it has net margins of 7.2%.

Key information

-1.7%

Earnings growth rate

-1.8%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate10.5%
Return on equity4.7%
Net Margin7.2%
Next Earnings Update04 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Pfizer makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BOVESPA:PFIZ34 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
29 Sep 2459,3754,27414,14810,595
30 Jun 2455,166-2,59314,13410,712
31 Mar 2454,889-28813,90810,665
31 Dec 2358,4962,13413,83610,679
01 Oct 2369,27410,46913,56811,420
02 Jul 2378,42021,49413,40011,435
02 Apr 2393,15429,03513,25811,621
31 Dec 22100,33031,36612,20011,428
02 Oct 2299,87829,95311,32511,260
03 Jul 22101,27529,48110,03211,243
03 Apr 2292,43325,4109,40010,667
31 Dec 2181,28822,4139,56210,360
03 Oct 2168,87719,4859,7149,972
04 Jul 2155,11912,23611,6769,589
04 Apr 2146,0849,03211,4549,184
31 Dec 2041,6516,63011,4188,709
27 Sep 2032,33421211,0068,084
28 Jun 2034,7376,97710,5657,727
29 Mar 2038,1379,42711,6377,716
31 Dec 1940,90510,70712,7667,721
29 Sep 1953,03916,21113,7557,891
30 Jun 1953,65612,63814,0507,948
31 Mar 1953,85911,46414,0047,914
31 Dec 1840,8253,82412,1497,713
30 Sep 1853,37323,80814,4817,827
01 Jul 1853,24422,54514,4927,686
01 Apr 1852,67321,74614,5097,673
31 Dec 1752,54621,30514,6067,645
01 Oct 1752,4719,79114,5467,843
02 Jul 1752,3478,30814,6087,861
02 Apr 1752,5987,28114,9597,826
31 Dec 1652,8247,19814,8947,858
02 Oct 1653,2436,27014,9567,652
03 Jul 1652,2867,03614,6977,797
03 Apr 1650,9927,61514,3397,787
31 Dec 1548,8516,94814,3257,646
27 Sep 1547,9228,36613,6407,366
28 Jun 1548,1968,91313,6667,135
29 Mar 1549,1169,20013,7767,118
31 Dec 1449,6059,08513,7207,150
28 Sep 1450,04510,46113,8946,902
29 Jun 1450,32710,37013,9446,740
30 Mar 1450,52710,99414,0096,546
31 Dec 1351,58411,33914,1646,551

Quality Earnings: PFIZ34 has a large one-off loss of $6.9B impacting its last 12 months of financial results to 29th September, 2024.

Growing Profit Margin: PFIZ34's current net profit margins (7.2%) are lower than last year (15.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PFIZ34's earnings have declined by 1.7% per year over the past 5 years.

Accelerating Growth: PFIZ34's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PFIZ34 had negative earnings growth (-60.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7.7%).

Return on Equity

High ROE: PFIZ34's Return on Equity (4.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 18:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pfizer Inc. is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Alistair CampbellBerenberg